BV100 is a new formulation of rifabutin suitable for intravenous administration that BioVersys claims offers a new mechanism ...

Ab&B Bio-Tech has joined the stacked roster of drug developers queuing up to go public in Hong Kong, filing the paperwork for ...

Arcos Dorados Holdings Inc. ARCO is a franchisee of McDonald’s restaurants. The Zacks Consensus Estimate for its current year ...

In pancreatic cancer, pelareorep previously demonstrated a strong efficacy signal when administered with gemcitabine, nab-paclitaxel and atezolizumab. Our new safety data indicate its ability to also ...

GSK’s share price has been pressured recently from several negative events, but this may leave a bargain to be had. I've ...

In an exclusive interview with SheKnows, Brooke Shields talked about aging, health, and how she talks about all of this with ...

The latest funding is a sign of how seriously the Biden administration appears to be taking the pandemic threat.

Jemperli (dostarlimab) in combination with chemotherapy (carboplatin and paclitaxel) for first-line treatment of adult ...

BioVersys is working on producing new antibiotics to tackle antimicrobial-resistant diseases. The IPO will help it take its ...

The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET ...

GSK (NYSE:GSK – Get Free Report) was downgraded by investment analysts at StockNews.com from a “strong-buy” rating to a “buy” ...

Swiss biopharma company BioVersys said on Tuesday it plans to list on the Swiss stock exchange in the first quarter with an initial public offering that aims to raise around 80 million Swiss francs ...